Opthea Limited, an Australian biologics drug developer focusing on ophthalmic disease therapies, has presented at the Ophthalmology Innovation Summit (OIS) in San Francisco. Dr Megan Baldwin, the company’s Chief Executive Officer, discussed a Phase 2b randomised controlled study of OPT-302 with Lucentis (ranibizumab) compared to Lucentis alone.
The presentation included an overview of the study design, safety outcomes and primary and secondary outcomes as well as an additional pre-specified exploratory analyses of the Phase 2b trial data, presented for the first time during the summit.
OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases.
Dr Baldwin said she was “delighted to present Opthea’s Phase 2b wet AMD study data for the first time in the US to professionals from the investor, pharmaceutical and clinical ophthalmology community”.
She acknowledged the event was a great “opportunity to provide further analyses from our Phase 2b study which demonstrated superior vision gains over 24 weeks in patients receiving OPT-302 combination therapy compared to Lucentis alone”.
OIS unites over 1200 representatives to collaborate on the development of innovative drugs, devices and diagnostics to address unmet vision disorders. The summit is held in conjunction with the annual meeting of the American Academy of Ophthalmology (AAO), one of the largest gatherings of ophthalmology healthcare specialists globally.
A copy of the presentation is available at www.opthea.com.
